Patient demographics and characteristics at baseline
| Characteristic . | |
|---|---|
| Sample size, n | 15 |
| Median age at therapy, y (range) | 29.3 (19.5-73.4) |
| Male, n (%) | 5 (33.3) |
| Stage, n (%) | |
| I/II | 7 (46.7) |
| III | 0 (0) |
| IV | 8 (53.3) |
| IPI, n (%) | |
| 0 | 1 (6.7) |
| 1 | 5 (33.3) |
| 2 | 5 (33.3) |
| 3 | 4 (26.7) |
| Systemic symptoms, n (%) | 5 (33.3) |
| Median LDH, U/L (range) | 569 (250-3196) |
| Refractory to most recent therapy, n (%) | 32 (74.4) |
| Median number of previous therapies (range) | 3 (1-4) |
| Prior autologous stem cell transplant, n (%) | 8 (53.3) |
| Prior radiotherapy, n (%) | 9 (60.0) |
| Characteristic . | |
|---|---|
| Sample size, n | 15 |
| Median age at therapy, y (range) | 29.3 (19.5-73.4) |
| Male, n (%) | 5 (33.3) |
| Stage, n (%) | |
| I/II | 7 (46.7) |
| III | 0 (0) |
| IV | 8 (53.3) |
| IPI, n (%) | |
| 0 | 1 (6.7) |
| 1 | 5 (33.3) |
| 2 | 5 (33.3) |
| 3 | 4 (26.7) |
| Systemic symptoms, n (%) | 5 (33.3) |
| Median LDH, U/L (range) | 569 (250-3196) |
| Refractory to most recent therapy, n (%) | 32 (74.4) |
| Median number of previous therapies (range) | 3 (1-4) |
| Prior autologous stem cell transplant, n (%) | 8 (53.3) |
| Prior radiotherapy, n (%) | 9 (60.0) |
IPI, International Prognostic Index; LDH, lactic acid dehydrogenase.